On (b)(6) 2020, the customer reported the patient had a new sample collected.The patient's results were tsh 26 uiu/ml with a data flag, ft4 0.94 ng/dl, and ft3 2.91 pg/ml.Also, the customer reported "during the last weeks no further thyroxin was taken by patient." the customer's calibration and qc data were requested but not provided.The investigation reproduced the customer's tsh results.Upon further investigation of the patient samples, an interferent against a component of the reagent was confirmed, ru-label.This interference is covered in product labeling: "in rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.These effects are minimized by suitable test design.For diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings." the investigation did not identify a product problem.
|